Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00543062 · ClinicalTrials.gov registry record · Phase 1
Staccato Prochlorperazine Thorough QT/QTc
A Phase 1 study, sponsored by Alexza Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT00543062 is a Phase 1 study that has completed, run by Alexza Pharmaceuticals. The registered enrollment target is 48 participants.
The verdict
NCT00543062, a Phase 1 study, has completed, sponsored by Alexza Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
To assess the safety of Staccato Prochlorperazine on cardiac repolarization (QTc interval duration) at 2 dose levels compared to placebo in healthy volunteers.
Interventions
- DRUG Oral placebo
- DRUG Inhaled placebo
- DRUG Oral moxifloxacin
- DRUG Inhaled prochlorperazine 5 mg
- DRUG Inhaled prochlorperazine 10 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2007-10 |
| Est. Completion | 2007-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00543062
The ClinicalTrials.gov registry entry for NCT00543062 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alexza Pharmaceuticals, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Oral placebo is the first listed.
NCT00543062 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00543062 about?
NCT00543062 is a clinical study titled "Staccato Prochlorperazine Thorough QT/QTc". To assess the safety of Staccato Prochlorperazine on cardiac repolarization (QTc interval duration) at 2 dose levels compared to placebo in healthy volunteers.
What is the current status of trial NCT00543062?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2007-10. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00543062?
The interventions under investigation include: Oral placebo (DRUG), Inhaled placebo (DRUG), Oral moxifloxacin (DRUG), Inhaled prochlorperazine 5 mg (DRUG), Inhaled prochlorperazine 10 mg (DRUG).
Who is sponsoring clinical trial NCT00543062?
This trial is sponsored by Alexza Pharmaceuticals, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.